financetom
Business
financetom
/
Business
/
Adidas three-stripe trademark ruled invalid by EU court
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Adidas three-stripe trademark ruled invalid by EU court
Jun 19, 2019 7:44 AM

Adidas' three-stripes have been ruled invalid as a trademark by a European Union court which said they lacked a distinctive character recognisable throughout the 28-country bloc.

But the German sporting goods company, whose shares were down 1.3 percent in a broadly weaker market, said the court's ruling on Wednesday only affects a particular use of the symbol.

The sporting goods industry has seen a rise in trademark and patent disputes as the biggest players try to differentiate their products and justify premium pricing.

High-profile cases have included Adidas clashing with Skechers USA and Nike taking on Puma.

The General Court of the European Union said it had upheld a 2016 decision of the European Intellectual Property Office (EUIPO) to annul a previous acceptance of the trademark, which Adidas registered in 2014 for clothing, footwear and headgear.

Adidas said its trademark consisted of "three parallel equidistant stripes of equal width applied to the product in whichever direction" but this was challenged by Belgium's Shoe Branding Europe after a decade-long dispute with Adidas.

The same EU court had rendered Shoe Branding's own two-stripe trademark invalid last year, saying the stripes were too similar to those of Adidas.

Shoe Branding bought Patrick, which was founded in 1892 and says it is the oldest sports brand in Europe, in 2008. Patrick features two stripes on its shoes and clothing.

Adidas needed to show the three stripe mark had acquired a "distinctive character" throughout the EU based on its use so that consumers inherently knew a product was from Adidas and could distinguish it from products of another company.

The court said the mark was not a pattern but an "ordinary figurative mark" and it was not relevant to take into account specific uses involving colours.

Adidas, which can still appeal to the European Court of Justice, said in a statement the ruling was limited to a "particular execution" of the three-stripe mark and did not impact other protected uses of the trademark in Europe. It was not immediately clear which use Adidas was referring to.

"Whilst we are disappointed with the decision, we are further evaluating it and are welcoming the useful guidance that the court will give us for protecting our 3-stripe mark applied to our products in whichever direction in the future," it said.

The court said Adidas had provided evidence related to the mark's use in five EU countries, but not throughout the bloc.

Geert Glas, an intellectual property lawyer at Allen & Overy in Brussels, said the decision seemed to be more based on the procedure and that Adidas should be able to produce evidence showing that the three stripes had distinctiveness in Europe.

"It's a setback for Adidas, but it shouldn’t be the end of their three stripes trademark," Glas said.

In other cases involving the big sporting goods players, Nike last year filed a lawsuit accusing German rival Puma of using patented athletic shoe technology without authorisation.

And a US appeals court said Adidas can protect its Stan Smith tennis shoe against an alleged Skechers knockoff, but that Skechers could sell another mimicking Adidas' three-stripes.

In 2017 a US judge rejected Adidas' effort to block Skechers from selling athletic sneakers that it said copied its "Springblade" concept.

First Published:Jun 19, 2019 4:44 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved